Dechert Advises Aquestive Therapeutics on $75MMM Strategic Funding Agreement with RTW
Dechert recently advised Aquestive Therapeutics on a $75 million strategic funding agreement with funds managed by RTW Investments, subject to United States Food and Drug Administration (FDA) approval of Anaphylm (epinephrine) Sublingual Film and other conditions. This financing provides critical...
Read moreDetails










